JAK2 and atherosclerosis: Although AIM2 inflammasome activation has been shown to be sufficient to promote atherosclerosis in Jak2 CH (15), our findings suggest that other pathways may also contribute to ASXL1-mediated CVD risk (Figure 3 and 4).